Ranibizumab News and Research

RSS

Antiangiogenic and anti-inflammatory drugs: are they safe?

Since Rofecoxib (Vioxx) was withdrawn from the worldwide market based on the safety findings of the Adenomatous Polyp Prevention on Vioxx (APPROVe) study, the uncertainty around the cardiovascular safety of NSAIDs and COX-2 inhibitors remains and leaves practitioners with difficult management decisions for the hundreds of millions of patients worldwide who continue to require pain-relieving therapy to maintain an acceptable quality of life.

1 Sep 2008

Ranibizumab therapy for diabetic eye disease shows promise

A JDRF collaboration between Johns Hopkins researchers and Genentech has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.

29 Apr 2008

FDA approves expansion of NeoVista's phase 3 study for wet AMD

NeoVista, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company's request to expand the number of sites participating in its pivotal Phase 3 trial from 10 to 30 in the United States.

17 Apr 2008

A view on new drugs for macular degeneration

Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is "unacceptable" concludes the July issue of Drug and Therapeutics Bulletin (DTB).

4 Jul 2007

Clinical trial of Ranibizumab for edema of the mAcula in diabetes

The Juvenile Diabetes Research Foundation, the world's largest charitable funder of type 1 diabetes research, announced that the Ranibizumab for Edema of the mAcula in Diabetes Phase 2 Study (READ 2) is now enrolling patients.

2 Apr 2007

New drug a breakthrough in the treatment of AMD

Age-related macular degeneration (AMD), is a common cause of vision loss and often affects older people.

5 Oct 2006

New drug restores sight in sufferers from AMD

A new drug with the capacity to reverse vision loss in some patients with age-related macular degeneration (AMD) has won approval from the Food and Drug Administration (FDA) in the U.S.

3 Jul 2006